Analysts’ Updated EPS Estimates for September 8th (ABM, ACIU, ARTL, ASO, BAB, BNTX, CER, CGON, CLSK, CRCL)

Analysts’ updated eps estimates for Monday, September 8th:

ABM Industries (NYSE:ABM) had its neutral rating reissued by analysts at Robert W. Baird. Robert W. Baird currently has a $54.00 price target on the stock, down from their previous price target of $56.00.

AC Immune (NASDAQ:ACIU) had its buy rating reissued by analysts at BTIG Research. The firm currently has a $8.00 target price on the stock.

Artelo Biosciences (NASDAQ:ARTL) had its hold rating reissued by analysts at D. Boral Capital.

Academy Sports and Outdoors (NASDAQ:ASO) had its buy rating reissued by analysts at Guggenheim. Guggenheim currently has a $60.00 target price on the stock.

Babcock International Group (LON:BAB) had its outperform rating reissued by analysts at Royal Bank Of Canada. They currently have a GBX 1,200 price target on the stock.

BioNTech (NASDAQ:BNTX) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $136.00 price target on the stock.

Cerillion (LON:CER) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They currently have a GBX 2,350 price target on the stock.

CG Oncology (NASDAQ:CGON) had its overweight rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $75.00 target price on the stock.

Cleanspark (NASDAQ:CLSK) had its buy rating reissued by analysts at Chardan Capital. The firm currently has a $20.00 price target on the stock.

Circle Internet Group (NYSE:CRCL) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $250.00 price target on the stock.

CervoMed (NASDAQ:CRVO) had its neutral rating reiterated by analysts at HC Wainwright. The firm currently has a $11.00 target price on the stock.

Denali Therapeutics (NASDAQ:DNLI) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald.

Dianthus Therapeutics (NASDAQ:DNTH) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $40.00 target price on the stock.

Docusign (NASDAQ:DOCU) had its hold rating reissued by analysts at Argus.

DexCom (NASDAQ:DXCM) was downgraded by analysts at Oppenheimer Holdings, Inc. from an outperform rating to a market perform rating.

e.l.f. Beauty (NYSE:ELF) had its strong-buy rating reiterated by analysts at Raymond James Financial, Inc.. They currently have a $155.00 target price on the stock, up from their previous target price of $140.00.

EMX Royalty (NYSEAMERICAN:EMX) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $5.75 price target on the stock.

enGene (NASDAQ:ENGN) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $25.00 target price on the stock.

Evolus (NASDAQ:EOLS) had its buy rating reissued by analysts at BTIG Research. BTIG Research currently has a $18.00 price target on the stock.

Gain Therapeutics (NASDAQ:GANX) had its buy rating reissued by analysts at BTIG Research. BTIG Research currently has a $9.00 target price on the stock.

Gibson Energy (TSE:GEI) was downgraded by analysts at BMO Capital Markets from an outperform rating to a market perform rating. They currently have C$27.00 target price on the stock, up from their previous target price of C$26.00.

ImmunityBio (NASDAQ:IBRX) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $24.00 price target on the stock.

I-Mab (NASDAQ:IMAB) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $6.00 target price on the stock.

Pulmonx (NASDAQ:LUNG) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $16.00 price target on the stock.

Mineralys Therapeutics (NASDAQ:MLYS) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $42.00 target price on the stock.

New Fortress Energy (NASDAQ:NFE) had its underweight rating reiterated by analysts at Capital One Financial Corporation.

NRx Pharmaceuticals (NASDAQ:NRXP) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $34.00 target price on the stock.

NRx Pharmaceuticals (NASDAQ:NRXP) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $40.00 target price on the stock.

Nuvation Bio (NYSE:NUVB) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $6.00 target price on the stock.

Nuvalent (NASDAQ:NUVL) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $115.00 target price on the stock.

OneConnect Financial Technology (NYSE:OCFT) was downgraded by analysts at Citigroup Inc. from a buy rating to a neutral rating. The firm currently has $7.98 price target on the stock, up from their previous price target of $3.03.

Pantheon Resources (LON:PANR) had its speculative buy rating reissued by analysts at Canaccord Genuity Group Inc.. They currently have a GBX 70 target price on the stock.

Personalis (NASDAQ:PSNL) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $8.50 price target on the stock.

uniQure (NASDAQ:QURE) had its buy rating reiterated by analysts at Chardan Capital. The firm currently has a $35.00 price target on the stock.

Replimune Group (NASDAQ:REPL) had its neutral rating reissued by analysts at HC Wainwright.

REGENXBIO (NASDAQ:RGNX) had its buy rating reiterated by analysts at Chardan Capital. The firm currently has a $52.00 price target on the stock.

REGENXBIO (NASDAQ:RGNX) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $34.00 target price on the stock.

RH (NYSE:RH) had its outperform rating reaffirmed by analysts at Telsey Advisory Group. They currently have a $255.00 target price on the stock.

Ryanair (NASDAQ:RYAAY) was downgraded by analysts at The Goldman Sachs Group, Inc. from a buy rating to a neutral rating.

Science Applications International (NYSE:SAIC) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $115.00 target price on the stock, down from their previous target price of $140.00.

Summit Therapeutics (NASDAQ:SMMT) had its buy rating reissued by analysts at HC Wainwright. They currently have a $50.00 target price on the stock.

Summit Therapeutics (NASDAQ:SMMT) had its overweight rating reiterated by analysts at Cantor Fitzgerald.

Skyworks Solutions (NASDAQ:SWKS) was downgraded by analysts at Wall Street Zen from a buy rating to a hold rating.

Transdigm Group (NYSE:TDG) was downgraded by analysts at Royal Bank Of Canada from an outperform rating to a sector perform rating. The firm currently has $1,385.00 target price on the stock, down from their previous target price of $1,550.00.

Trade Desk (NASDAQ:TTD) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $84.00 target price on the stock.

Texas Instruments (NASDAQ:TXN) had its buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $220.00 target price on the stock.

Ulta Beauty (NASDAQ:ULTA) had its outperform rating reiterated by analysts at Telsey Advisory Group. The firm currently has a $610.00 price target on the stock.

AB Volvo (OTCMKTS:VLVLY) was downgraded by analysts at The Goldman Sachs Group, Inc. from a buy rating to a neutral rating.